In the healthcare space, ARK also added to its holdings in Veracyte Inc (NASDAQ: VCYT ), buying 87,248 shares worth about $2.18 million. This trade aligns with ARK’s focus on innovative companies with ...

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing ...

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July ...

Biotechnology company Veracyte (VCYT) is set to replace Triumph Group (TGI) in the S&P SmallCap 600 index prior to the market open on Tuesday, July 29.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, ...

Yet, persistent supply chain challenges plaguing the aerospace sector remain a concern. Afirma Solution's Outperformance Aid Veracyte (VCYT) ...

On Friday, Cathie Wood -led Ark Invest made significant trades, with a particular focus on the tech and hospitality sectors. The most prominent trades of the day involved shares of Airbnb Inc.

Veracyte, Inc. (NASDAQ:VCYT) generated revenue of $114.5 million in the first quarter of fiscal 2025, marking a 18% increase from last year’s comparable quarter.

Veracyte (VCYT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

Veracyte (VCYT) delivered earnings and revenue surprises of 55% and 3.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?